Drug profile · INN
nirmatrelvir
PAXLOVID
nirmatrelvir (PAXLOVID) is a sars coronavirus 3c-like proteinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — nirmatrelvir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
nirmatrelvir (PAXLOVID) is a sars coronavirus 3c-like proteinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
SARS coronavirus 3C-like proteinase inhibitor
Primary target: Replicase polyprotein 1a
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nirmatrelvir?
nirmatrelvir (PAXLOVID) is a sars coronavirus 3c-like proteinase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nirmatrelvir?
PAXLOVID is a marketed brand name for nirmatrelvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nirmatrelvir?
nirmatrelvir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.